Innovative Target for Pancreatic Cancer Treatment Identified by Researchers

Researchers at the University of Cincinnati Cancer Center are pioneering a novel approach to combat pancreatic ductal adenocarcinoma (PDAC), one of the most lethal forms of cancer with a dismal five-year survival rate of below 10%. Their groundbreaking study has unveiled a critical protein that contributes to the tumor's resistance to treatment, leading to the development of a new drug specifically targeting this protein.

The research team explored the distinctive tumor microenvironment of PDAC, which includes the tumor itself, surrounding immune cells, blood vessels, and other tissues. They discovered that this unique environment not only suppresses the immune system's ability to fight the cancer but also obstructs drug delivery and promotes resistance to various therapies, including chemotherapy and immunotherapy.

Dr. Ahmet Kaynak, a postdoctoral fellow in the Hematology & Oncology Division at UC's College of Medicine, emphasized the pressing need for innovative treatment strategies in light of these challenges. The research aimed to identify the factors that precipitate immunosuppression within the tumor microenvironment.

Through their investigations, the team identified a protein known as Hsp70 as a significant contributor to tumor-induced immunosuppression. While the essential role of Hsp70 in cellular homeostasis has been recognized, its specific function in fostering an immunosuppressive environment around tumors was not widely acknowledged prior to this study.

Building on the findings related to Hsp70, the researchers developed a new therapeutic agent named SapC-DOPG. This drug is designed to target cancer cells by binding to phosphatidylserine, a lipid found on the surface of these cells. This advancement builds upon earlier work by Dr. Xiaoyang Qi, who created a similar compound, SapC-DOPS, which is currently undergoing Phase 2 clinical trials for lung cancer.

Preliminary testing in animal models has shown that SapC-DOPG is well tolerated and achieves promising outcomes, including reduced tumor size and extended survival rates. Dr. Kaynak expressed hopes of transitioning this research into clinical trials, aiming to evaluate the safety and efficacy of SapC-DOPG in patients with pancreatic cancer.

The initial safety of the analog SapC-DOPS has already been demonstrated in clinical trials involving human patients, providing a foundation for the potential application of SapC-DOPG. The research team is optimistic about the future of this drug as a viable therapeutic option for pancreatic cancer patients.

Dr. Kaynak's contributions to this research have been recognized, with one of his publications being honored as the Cancer Center's Trainee Associate Membership Paper of the Year. He attributes his success to the mentorship and support received from Dr. Qi and the Hematology and Oncology Division at UC.

As the research progresses, it underscores the importance of continued exploration into the mechanisms of pancreatic cancer and the development of targeted therapies that could significantly improve outcomes for patients battling this devastating disease.